集泰股份(002909.SZ):公司產品未出口至美國
格隆匯4月10日丨集泰股份(002909.SZ)在互動平臺表示,出口方面,2024年公司外貿銷售收入佔比爲2.32%,且主要出口市場集中在亞洲、澳洲及"一帶一路"沿線國家,公司產品未出口至美國。進口方面,公司的原材料供應鏈安全保障體系運行有效,公司原材料以國產爲主,且僅有微量助劑從美國進口,該部分助劑可以採取國產或其他國家進口的方案替代。基於上述業務結構,當前美國關稅政策對公司進出口業務整體影響微乎其微。同時,公司深耕本土市場多年,將依託本土化快速響應優勢,通過深化重點區域市場佈局、優化產品結構等方式把握國內市場進口替代機遇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.